Latest News and Press Releases

Dublin, May 27, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines,...

Austin, TX, USA, May 19, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Cholera Vaccine Market Size, Trends and Insights By Type (Whole Cell v. Cholerae...

Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 20261Program launched in April to...

Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 20261Lancement,...

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Dukoral Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

Lyon (France), May 6 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May...

Lyon (France), le 6 mai 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers du premier...

VALNEVA Declaration of shares and voting rights Status as of April 30, 2026 taking into account interim information as at May 5,...

VALNEVA Déclaration d’actions et de droits de vote Statut au 30 avril 2026 tenant compte d’informations intermédiaires au 5 mai...

Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday,...